Nabriva Therapeutics PLC (NBRV)
| Market Cap | 61.55M |
| Revenue (ttm) | 2.90M |
| Net Income (ttm) | -74.70M |
| Shares Out | 14.47M |
| EPS (ttm) | -6.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $2.92 |
| Previous Close | $3.05 |
| Change ($) | -0.13 |
| Change (%) | -4.26% |
| Day's Open | 3.09 |
| Day's Range | 2.77 - 3.08 |
| Day's Volume | 901,879 |
| 52-Week Range | 2.37 - 16.20 |
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and developmen...
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and developmen...
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and developmen...
- Amen ded agreement encompasses enhanced manufacturing collaboration and regulatory support
DUBLIN, Ireland, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infe...
Nabriva Therapeutics plc's (NBRV) CEO Ted Schroeder on Q3 2020 Results - Earnings Call Transcript
-Relaunch of Xenleta® and Sivextro® commenced in late September-
DUBLIN, Ireland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infe...
-- Findings underscore potential of XENLETA as a first-in-class pleuromutilin antibiotic for the IV and oral treatment of CABP in adults, including older patients with comorbidities who are at...
-NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship
Nabriva Therapeutics Plc (NBRV) CEO Ted Schroeder on Q2 2020 Results - Earnings Call Transcript
DUBLIN, Ireland, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-in...
DUBLIN, Ireland, July 30, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-in...
Nabriva (NBRV) will provide updates on its drugs and revenues when it releases second-quarter 2020 results.
- XENLETA represents the first new antibiotic class approved for patients with CAP in Europe in nearly 20 years
-In pre-clinical model, lefamulin shows anti-inflammatory activity comparable to dexamethasone
-XENLETA to be marketed exclusively in Canada by Sunovion Pharmaceuticals Canada Inc. -XENLETA to be marketed exclusively in Canada by Sunovion Pharmaceuticals Canada Inc.
Nabriva (NBRV) signs a contract with the units of Merck for selling and distributing the latter's antibiotic Sivextro in the United States. Shares rise in pre-market trading.
DUBLIN, Ireland and KING OF PRUSSIA, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and developm...
Agency Cited Travel Restrictions and Inability to Conduct Onsite Inspections to Resolve Observations at Manufacturing Partner Facilities Agency Cited Travel Restrictions and Inability to Condu...
Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.
As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics.
Investors need to pay close attention to Nabriva (NBRV) stock based on the movements in the options market lately.
DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 29, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and developme...
Large, contemporary, cross-sectional study highlights the urgent need for local epidemiology data to be available to inform empiric antibiotic choices that are concordant with the IDSA/ATS com...
Nabriva Therapeutics Plc (NBRV) CEO Ted Schroeder on Q1 2020 Results - Earnings Call Transcript
Nabriva Therapeutics (NBRV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Results support Xenleta as an empiric, short-course monotherapy replacement for respiratory fluoroquinolones for treatment of CABP Results support Xenleta as an empiric, short-course monothera...
Nabriva Therapeutics (NBRV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
DUBLIN, Ireland, April 09, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-i...
DUBLIN, Ireland, April 08, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-i...
Nabriva (NBRV) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Nabriva Therapeutics' (NBRV) CEO Ted Schroeder on Q4 2019 Results - Earnings Call Transcript
DUBLIN, Ireland, March 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-i...
DUBLIN, Ireland, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-in...
As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics.
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and developm...
Shares of Nabriva Therapeutics PLC NBRV, -3.37% soared 10.5% in premarket trading Friday, after the biotechnology company said it resubmitted its new drug application (NDA) for Contepo, its tr...
-Nabriva anticipates a six-month review period by the Food and Drug Administration
DUBLIN, Ireland, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-in...
Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV) shares have gained about 46% year-to-date.
Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q3 2019 Results - Earnings Call Transcript
Investors want to know which stocks are set to take flight. We are talking about stocks with serious growth prospects here, or names that can more than double investors’ returns in the next year.
Poster sessions to highlight pooled results from the pivotal LEAP 1 and LEAP 2 Phase 3 clinical trials Poster sessions to highlight pooled results from the pivotal LEAP 1 and LEAP 2 Phase 3 cl...
Nabriva publication of Phase 3 clinical trial results highlights efficacy of XENLETA™ (lefamulin tablets) as novel, short-course, empiric monotherapy for adults with community-acquired bacteri...
DUBLIN, Ireland, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-i...
Today, we look at Nabriva Therapeutics which has received a tepid reception for the FDA approval of its antibiotic Xenleta on August 19th, 2019.
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and develop...
First IV and oral antibiotic with novel mechanism of action approved by the FDA in nearly two decades, targets the most common CABP pathogens and supports antibiotic stewardship First IV and o...
DUBLIN, Ireland, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-i...
About NBRV
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; for the treatment of acute bacterial skin and skin structure infection; and that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, osteomyelitis, and prosthetic joint... [Read more...]
| Industry Biotechnology | IPO Date Sep 18, 2015 |
| CEO Theodore Schroeder | Employees 162 |
| Stock Exchange NASDAQ | Ticker Symbol NBRV |
Financial Performance
In 2019, NBRV's revenue was $9.48 million, a decrease of -1.81% compared to the previous year's $9.66 million. Losses were -$82.76 million, -27.89% less than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for NBRV stock is "Buy." The 12-month stock price forecast is 9.00, which is an increase of 208.22% from the latest price.